Immucell Corp /De/ (NASDAQ: ICCC)

ImmuCell Corporation is an animal health biologics company that develops manufactures and commercializes products intended to improve the survivability health and long term performance of neonatal dairy and beef calves. The company’s primary focus is on preventing calf scours a leading cause of pre weaning mortality that accounts for thirty to forty percent of losses in many production systems worldwide. Its core product line First Defense® uses hyperimmunized bovine colostrum to deliver pathogen specific antibodies that provide immediate immunity against the principal viral and bacterial causes of neonatal diarrhea. First Defense® is available in several formats including single dose boluses gel syringes and multi dose powder packs that are administered at or shortly after birth. In addition to the First Defense® line ImmuCell offers a California Mastitis Test for on farm detection of udder inflammation and functional feed ingredients derived from the same colostrum source. Manufacturing involves proprietary vaccine development dairy herd hyperimmunization colostrum sourcing antibody concentration purification blending fill finish and final product testing with some formats produced by third party contractors.

ImmuCell generates revenue primarily from the sale of its First Defense® products which are sold as single dose boluses gel syringes and multi dose powder packs to dairy and beef producers. The company also earns income from the California Mastitis Test and from functional feed ingredients that are incorporated into liquid feeding programs for larger calf rearing operations. Sales are executed through ImmuCell’s own commercial sales team that works in partnership with a network of international national and regional animal health distributors. Distributors in turn supply veterinary clinics farm supply stores and direct farm customers ensuring broad geographic coverage. The business experiences seasonal demand with higher sales in the 1st quarter driven by the beef calving season which runs from January to April. Although warm dry weather can reduce perceived need for disease prevention heat or cold stress on calves can increase scours incidence and support continued product use throughout the year.

• no_segments_reported.

ImmuCell competes in the calf health market against large animal health companies such as Zoetis, Elanco, Merck, Boehringer Ingelheim and CEVA which primarily market vaccine based scours preventives. Unlike vaccines that rely on stimulating the calf’s immune system to produce antibodies, ImmuCell’s First Defense® delivers pre formed pathogen specific antibodies directly to the newborn calf. This approach provides immediate passive immunity during the highest risk period without dependence on the timing variability or biological cost of an active immune response. Studies indicate that First Defense® supplies three to six times the level of neutralizing antibodies compared with leading vaccines supporting its price premium and strong return on investment for producers. The brand also benefits from organic certification for certain formats which expands its appeal to certified dairy and beef producers seeking natural solutions. ImmuCell’s strategy emphasizes increasing market share through expanded sales force outreach, international market entry, product line extensions and capacity expansion using existing facilities.

ImmuCell serves commercial dairy operations, specialized calf ranches and beef producers that manage newborn calves during the 1st weeks of life. Products reach end users through veterinary clinics, farm supply stores and direct farm sales facilitated by the distributor network. The company’s products are used across the United States, Canada and increasingly in international markets. ImmuCell estimates that approximately 55% of calves in the United States are not yet protected by a biological scours prevention product representing a significant opportunity for expanded adoption. Based on market data the company notes that spend on biological scours preventives exceeded $90 million in 2025 and has been growing at a rate above 10% per year driven by rising calf values and increased awareness of prevention solutions.